Article
Version 1
Preserved in Portico This version is not peer-reviewed
Does COVID-19 Really Exacerbate Urticaria? A Survey of 166 Patients in China
Version 1
: Received: 2 November 2023 / Approved: 3 November 2023 / Online: 3 November 2023 (11:12:59 CET)
A peer-reviewed article of this Preprint also exists.
Yang, Q.; Zou, Z.; Cao, W.; Shi, Y.; Xiao, X.; Chen, S.; Li, Y. Does COVID-19 Really Exacerbate Urticaria? A Survey of 166 Patients in China. COVID 2023, 3, 1707-1720. Yang, Q.; Zou, Z.; Cao, W.; Shi, Y.; Xiao, X.; Chen, S.; Li, Y. Does COVID-19 Really Exacerbate Urticaria? A Survey of 166 Patients in China. COVID 2023, 3, 1707-1720.
Abstract
Abstract: The COVID-19 pandemic significantly disrupted global healthcare systems. The impacts of SARS-CoV-2 infection on urticaria and its management are unknown. To collect information about patients with urticaria infected with SARS-CoV-2 and to investigate the impact of SARS-CoV-2 infection on urticaria severity, course, and treatment to better support recovery. This was a questionnaire-based study of patients with urticaria infected with SARS-CoV-2. Changes in urticaria severity (measured with the urticaria activity score (UAS)), course, and treatment were assessed before, during, and after SARS-CoV-2 infection. Mean (± SD) UAS scores were 5.17 ± 1.67, 4.23 ± 1.98, and 4.37 ± 1.93 before, during, and after SARS-CoV-2 infection, respectively (F = 8.839, p < 0.01). The median (IQR) wheal score was 0.464 (0.464, 0.763), 0.464 (0.138, 0.763), and 0.464 (0.138, 0.763) before, during, and after infection, respectively (Kruskal-Wallis H-test, H=12.230, p = 0.02). The median (IQR) pruritus score was 0.695 (0.395, 0.695), 0.394 (0.123, 0.695), and 0.394 (0.123, 0.695) before, during, and after infection, respectively (Kruskal-Wallis H-test, H = 21.001, p < 0.01). Within the limitations of a questionnaire study, urticaria appears to improve during SARS-CoV-2 infection, worsens slightly after recovery, and the frequency of Western medicine use increases.
Keywords
Urticaria; SARS-CoV-2 infection; COVID-19 pandemic; mast cells
Subject
Public Health and Healthcare, Public Health and Health Services
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment